Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.

Zixi WangHuaiyuan ZongWeiwei LiuWei LinAnjiang SunZhao DingXu ChenXiaofeng WanYanyan LiuZhongdong HuHongbing ZhangHongwu LiYehai LiuDapeng LiSumei ZhangXiaojun Zha

Published in: Journal of experimental & clinical cancer research : CR (2024)

The ERO1α/IL-6/STAT3/SLC7A11 pathway is crucial for mTORC1-mediated ferroptosis resistance and tumor growth, and combining ERO1α inhibition with ferroptosis inducers is a novel and effective treatment for mTORC1-related tumors.

Keyphrases

cell death
poor prognosis
cell proliferation
signaling pathway
long non coding rna
combination therapy
replacement therapy